Loading...
OTCMSGIOY
Market cap11bUSD
Dec 24, Last price  
7.00USD
1D
0.29%
1Q
-35.72%
Jan 2017
-92.41%
Name

Shionogi & Co Ltd

Chart & Performance

D1W1MN
OTCM:SGIOY chart
P/E
5.77
P/S
2.15
EPS
190.47
Div Yield, %
736.81%
Shrs. gr., 5y
-1.66%
Rev. gr., 5y
3.65%
Revenues
435.08b
+1.97%
199,365,000,000196,389,000,000199,759,000,000214,268,000,000227,511,000,000278,502,000,000282,350,000,000267,275,000,000282,903,000,000289,717,000,000273,991,000,000309,973,000,000338,890,000,000344,667,000,000363,721,000,000333,371,000,000297,177,000,000335,138,000,000426,684,000,000435,081,000,000
Net income
162.03b
-12.40%
18,942,000,00022,735,000,00018,595,000,00025,064,000,00015,661,000,00038,625,000,00020,026,000,00027,101,000,00066,727,000,00041,831,000,00044,060,000,00066,687,000,00083,879,000,000108,866,000,000132,759,000,000122,193,000,000111,858,000,000114,185,000,000184,965,000,000162,030,000,000
CFO
154.28b
-13.26%
28,549,000,00016,885,000,00014,116,000,00015,619,000,00029,120,000,00052,901,000,00056,528,000,00054,724,000,00059,276,000,00079,496,000,00045,604,000,000102,290,000,000111,903,000,000129,790,000,000145,684,000,000131,940,000,000109,039,000,000102,068,000,000177,867,000,000154,284,000,000
Dividend
Sep 28, 20230.086021 USD/sh
Earnings
Jan 29, 2025

Profile

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
URL
https://www.shionogi.co.jp/
IPO date
May 16, 1949
Employees
5,680
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
435,081,000
1.97%
426,684,000
27.32%
335,138,000
12.77%
Cost of revenue
263,621,000
269,932,000
230,163,000
Unusual Expense (Income)
NOPBT
171,460,000
156,752,000
104,975,000
NOPBT Margin
39.41%
36.74%
31.32%
Operating Taxes
37,708,000
35,836,000
12,829,000
Tax Rate
21.99%
22.86%
12.22%
NOPAT
133,752,000
120,916,000
92,146,000
Net income
162,030,000
-12.40%
184,965,000
61.99%
114,185,000
2.08%
Dividends
(43,876,000)
(36,142,000)
(33,146,000)
Dividend yield
1.95%
2.03%
1.46%
Proceeds from repurchase of equity
(75,182,000)
(49,539,000)
(14,000)
BB yield
3.34%
2.78%
0.00%
Debt
Debt current
2,867,000
3,014,000
2,945,000
Long-term debt
20,373,000
15,808,000
10,403,000
Deferred revenue
17,711,000
21,028,000
Other long-term liabilities
17,337,000
1,346,000
356,000
Net debt
(654,939,000)
(825,342,000)
(727,035,000)
Cash flow
Cash from operating activities
154,284,000
177,867,000
102,068,000
CAPEX
(28,267,000)
(37,187,000)
(31,564,000)
Cash from investing activities
5,922,000
(48,292,000)
(96,204,000)
Cash from financing activities
(126,853,000)
(84,123,000)
(36,615,000)
FCF
(122,327,000)
122,044,000
43,975,000
Balance
Cash
358,090,000
563,355,000
465,177,000
Long term investments
320,089,000
280,809,000
275,206,000
Excess cash
656,424,950
822,829,800
723,626,100
Stockholders' equity
1,376,206,000
2,083,763,000
1,847,522,000
Invested Capital
625,093,050
285,299,200
279,743,900
ROIC
29.38%
42.80%
37.36%
ROCE
13.33%
14.07%
10.38%
EV
Common stock shares outstanding
290,210
297,805
301,579
Price
7,750.00
29.66%
5,977.00
-20.62%
7,530.00
26.51%
Market cap
2,249,126,841
26.36%
1,779,980,485
-21.62%
2,270,889,870
24.46%
EV
1,611,423,841
1,890,487,485
2,372,315,870
EBITDA
189,783,000
173,917,000
121,326,000
EV/EBITDA
8.49
10.87
19.55
Interest
6,701,000
4,500,000
841,000
Interest/NOPBT
3.91%
2.87%
0.80%